Aya Iriyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aya Iriyama has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Yasuo Yanagi
Department of Ophthalmology and Micro-technology, Yokohama City University, Yokohama, Japan
5 shared publications Yasuhiro Tamaki
From the *Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan; †Department of Ophthalmology, University of Tokyo School of Medicine, Tokyo, Japan; and ‡Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan
3 shared publicationsKazunori Kataoka
Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Bunkyo, Tokyo, Japan
2 shared publications- Makoto Oba
Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 1–5 Shimogamohangi-cho, Sakyo-ku, Kyoto 606-0823, Japan
2 shared publications - Nobuhiro Nishiyama
Institute of Science Tokyo 4259 Nagatsuta-cho, Midori-ku
2 shared publications Kanjiro Miyata
1 shared publication
Latest Publications
- 1 July 2013
- Published by Wolters Kluwer Health in Retina
- Vol. 33 (7) , 1462-1465
OUTER RETINAL TUBULATION IN INHERITED RETINAL DEGENERATIVE DISEASE
Purpose: To investigate the prevalence and characteristics of outer retinal tubulation (ORT) seen in inherited retinal degenerative diseases. Methods: A total of 354 eyes of 177 patients were examined with spectral domain optical coherence tomography. One hundred and twelve patients had retinitis pigmentosa, 58 patients had cone dystrophy, and 7 patients had the Bietti crystalline dystrophy. The images obtained by horizontal and vertical scans were analyzed to explore the possible presence of ORT, estimate their prevalence, morphologic character, and their location in the retinal layers. Results: With spectral domain optical coherence tomography, ORT was identified in 0 of 112 patients with retinitis pigmentosa, unilaterally in 3 of 58 patients with cone dystrophy, and bilaterally in 5 of 7 patients with the Bietti crystalline dystrophy. Outer retinal tubulation was detected under the fovea, and in the outer nuclear layer, ORT was detected in the Bietti crystalline dystrophy with a significantly higher frequency than in cone dystrophy (P < 0.001). Conclusion: There was a higher rate of ORT in the Bietti crystalline dystrophy among inherited retinal degenerative diseases.
- 1 July 2013
- Published by Wolters Kluwer Health in Retina
- Vol. 33 (7) , 1462-1465
OUTER RETINAL TUBULATION IN INHERITED RETINAL DEGENERATIVE DISEASE
Purpose: To investigate the prevalence and characteristics of outer retinal tubulation (ORT) seen in inherited retinal degenerative diseases. Methods: A total of 354 eyes of 177 patients were examined with spectral domain optical coherence tomography. One hundred and twelve patients had retinitis pigmentosa, 58 patients had cone dystrophy, and 7 patients had the Bietti crystalline dystrophy. The images obtained by horizontal and vertical scans were analyzed to explore the possible presence of ORT, estimate their prevalence, morphologic character, and their location in the retinal layers. Results: With spectral domain optical coherence tomography, ORT was identified in 0 of 112 patients with retinitis pigmentosa, unilaterally in 3 of 58 patients with cone dystrophy, and bilaterally in 5 of 7 patients with the Bietti crystalline dystrophy. Outer retinal tubulation was detected under the fovea, and in the outer nuclear layer, ORT was detected in the Bietti crystalline dystrophy with a significantly higher frequency than in cone dystrophy (P < 0.001). Conclusion: There was a higher rate of ORT in the Bietti crystalline dystrophy among inherited retinal degenerative diseases.
- 1 March 2012
- Published by Wolters Kluwer Health in Retina
- Vol. 32 (3) , 613-616
EFFECT OF BRILLIANT BLUE G ON THE RETINAL GANGLION CELLS OF RATS
Purpose: To investigate the effects of Brilliant Blue G (BBG) on rat retinal ganglion cells (RGCs), both in vitro and in vivo. Methods: In vitro, rat RGCs were purified by a 2-step immunopanning procedure, briefly exposed to BBG (250 mg/L), and irradiated with an endoilluminator for 15 minutes or incubated in the presence of BBG (concentration, 2–250 mg/L) without irradiation. The number of viable RGCs was counted after 3 days in culture. In vivo, after rats received an intravitreal injection of 3 μL of BBG (0.25 and 2.5 mg/L), the number of viable RGCs was examined by a 1,1'-dioctadecyl-1-3,3,3',3'-tetramethylindocarbocyanine perchlorate–retrolabeling technique. Results: In vitro, a brief exposure to BBG and irradiation did not affect RGC survival. However, BBG reduced the number of viable RGCs in a dose-dependent manner when the cells were exposed for 3 days. In vivo, when rats received an intravitreous injection of 0.25 mg/L BBG, the number of viable RGCs was not affected. The number of viable RGCs showed a tendency to decrease in the 2.5-mg/L group 14 days after the injection, but the difference was not significant compared with the number in the saline-treated control group. Conclusion: Brilliant Blue G exerts no detectable detrimental effect on RGCs after short-time exposure, and no significant toxic effect even after a longer-time exposure in the current experimental setting.
- 1 March 2012
- Published by Wolters Kluwer Health in Retina
- Vol. 32 (3) , 613-616
EFFECT OF BRILLIANT BLUE G ON THE RETINAL GANGLION CELLS OF RATS
Purpose: To investigate the effects of Brilliant Blue G (BBG) on rat retinal ganglion cells (RGCs), both in vitro and in vivo. Methods: In vitro, rat RGCs were purified by a 2-step immunopanning procedure, briefly exposed to BBG (250 mg/L), and irradiated with an endoilluminator for 15 minutes or incubated in the presence of BBG (concentration, 2–250 mg/L) without irradiation. The number of viable RGCs was counted after 3 days in culture. In vivo, after rats received an intravitreal injection of 3 μL of BBG (0.25 and 2.5 mg/L), the number of viable RGCs was examined by a 1,1'-dioctadecyl-1-3,3,3',3'-tetramethylindocarbocyanine perchlorate–retrolabeling technique. Results: In vitro, a brief exposure to BBG and irradiation did not affect RGC survival. However, BBG reduced the number of viable RGCs in a dose-dependent manner when the cells were exposed for 3 days. In vivo, when rats received an intravitreous injection of 0.25 mg/L BBG, the number of viable RGCs was not affected. The number of viable RGCs showed a tendency to decrease in the 2.5-mg/L group 14 days after the injection, but the difference was not significant compared with the number in the saline-treated control group. Conclusion: Brilliant Blue G exerts no detectable detrimental effect on RGCs after short-time exposure, and no significant toxic effect even after a longer-time exposure in the current experimental setting.
- Open Access
- 5 December 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (12) , e28560
Gene Transfer Using Micellar Nanovectors Inhibits Choroidal Neovascularization In Vivo
Age-related macular degeneration caused by choroidal neovascularization (CNV) remains difficult to be treated despite the recent advent of several treatment options. In this study, we investigated the in vivo angiogenic control by intravenous injection of polyion complex (PIC) micelle encapsulating plasmid DNA (pDNA) using a mice CNV model. The transfection efficiency of the PIC micelle was investigated using the laser-induced CNV in eight-week-old male C57 BJ/6 mice. Firstly, each mouse received intravenous injection of micelle encapsulating pDNA of Yellow Fluorescent Protein (pYFP) on days 1,3 and 5. The expression of YFP was analyzed using fluorescein microscopy and western blotting analysis. In the next experiments, each mouse received intravenous injection of micelle encapsulating pDNA of soluble Fms-like tyrosine kinase-1 (psFlt-1) 1,3 and 5 days after the induction of CNV and the CNV lesion was analyzed by choroidal flatmounts on day 7. Fluorescein microscopy and western blotting analysis revealed that the expression of YFP was confirmed in the CNV area after injection of the PIC micelle, but the expression was not detected neither in mice that received naked pDNA nor those without CNV. Furthermore, the CNV area in the mice that received intravenous injection of the psFlt-1-encapsulated PIC micelle was significantly reduced by 65% compared to that in control mice (p<0.01). Transfection of sFlt-1 with the PIC micelle by intravenous injection to mice CNV models showed significant inhibition of CNV. The current results revealed the significant potential of nonviral gene therapy for regulation of CNV using the PIC micelle encapsulating pDNA.
- 5 December 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (12) , e28560
Open AccessGene Transfer Using Micellar Nanovectors Inhibits Choroidal Neovascularization In Vivo
Age-related macular degeneration caused by choroidal neovascularization (CNV) remains difficult to be treated despite the recent advent of several treatment options. In this study, we investigated the in vivo angiogenic control by intravenous injection of polyion complex (PIC) micelle encapsulating plasmid DNA (pDNA) using a mice CNV model. The transfection efficiency of the PIC micelle was investigated using the laser-induced CNV in eight-week-old male C57 BJ/6 mice. Firstly, each mouse received intravenous injection of micelle encapsulating pDNA of Yellow Fluorescent Protein (pYFP) on days 1,3 and 5. The expression of YFP was analyzed using fluorescein microscopy and western blotting analysis. In the next experiments, each mouse received intravenous injection of micelle encapsulating pDNA of soluble Fms-like tyrosine kinase-1 (psFlt-1) 1,3 and 5 days after the induction of CNV and the CNV lesion was analyzed by choroidal flatmounts on day 7. Fluorescein microscopy and western blotting analysis revealed that the expression of YFP was confirmed in the CNV area after injection of the PIC micelle, but the expression was not detected neither in mice that received naked pDNA nor those without CNV. Furthermore, the CNV area in the mice that received intravenous injection of the psFlt-1-encapsulated PIC micelle was significantly reduced by 65% compared to that in control mice (p<0.01). Transfection of sFlt-1 with the PIC micelle by intravenous injection to mice CNV models showed significant inhibition of CNV. The current results revealed the significant potential of nonviral gene therapy for regulation of CNV using the PIC micelle encapsulating pDNA.
- 1 December 2011
- Published by Wolters Kluwer Health in Cornea
- Vol. 30 (12) , 1423-1427
Gene Transfer Using Micellar Nanovectors Inhibits Corneal Neovascularization In Vivo
Purpose: The efficacy of gene therapy using nonviral vector based on polyplex micelle has been studied against corneal neovascularization in mice. Methods: A block copolymer, poly(ethylene glycol) (PEG)-block-polycation carrying ethylenediamine units in the side chain (PEG-b-P[Asp(DET)]), was prepared. PEG-b-P[Asp(DET)] formed a polyplex micelle through the polyion complex formation with plasmid DNA. To evaluate in vivo gene transfer efficiency, PEG-b-P[Asp(DET)] micelle was injected into the subconjunctival space of mice, and the expression of the reporter gene was assessed. Furthermore, mouse corneal neovascularization models were treated with the PEG-b-P[Asp(DET)] polyplex micelle containing expression plasmid vector of soluble vascular endothelial growth factor receptor 1 (sflt-1). Results: Subconjunctival injection of the PEG-b-P[Asp(DET)] polyplex micelle containing a reporter gene showed prolonged gene expression with low cytotoxicity. Also, gene transfer into subconjunctival space by the polyplex micelle containing sflt-1 plasmid showed significant inhibition of corneal neovascularization in mice. Conclusions: Nonviral gene therapy using PEG-b-P[Asp(DET)] polyplex micelle may have potential for safe and effective therapeutic treatment of corneal neovascularization.
- 1 December 2011
- Published by Wolters Kluwer Health in Cornea
- Vol. 30 (12) , 1423-1427
Gene Transfer Using Micellar Nanovectors Inhibits Corneal Neovascularization In Vivo
Purpose: The efficacy of gene therapy using nonviral vector based on polyplex micelle has been studied against corneal neovascularization in mice. Methods: A block copolymer, poly(ethylene glycol) (PEG)-block-polycation carrying ethylenediamine units in the side chain (PEG-b-P[Asp(DET)]), was prepared. PEG-b-P[Asp(DET)] formed a polyplex micelle through the polyion complex formation with plasmid DNA. To evaluate in vivo gene transfer efficiency, PEG-b-P[Asp(DET)] micelle was injected into the subconjunctival space of mice, and the expression of the reporter gene was assessed. Furthermore, mouse corneal neovascularization models were treated with the PEG-b-P[Asp(DET)] polyplex micelle containing expression plasmid vector of soluble vascular endothelial growth factor receptor 1 (sflt-1). Results: Subconjunctival injection of the PEG-b-P[Asp(DET)] polyplex micelle containing a reporter gene showed prolonged gene expression with low cytotoxicity. Also, gene transfer into subconjunctival space by the polyplex micelle containing sflt-1 plasmid showed significant inhibition of corneal neovascularization in mice. Conclusions: Nonviral gene therapy using PEG-b-P[Asp(DET)] polyplex micelle may have potential for safe and effective therapeutic treatment of corneal neovascularization.
- 2 May 2007
- Published by BMJ in British Journal of Ophthalmology
- Vol. 91 (9) , 1230-1233
Effect of anti-VEGF antibody on retinal ganglion cells in rats
Aim: Intravitreal injection of anti-vascular endothelial growth factor (VEGF) antibody (bevacizumab, Avastin) has become one of the chief choices for the treatment of macular oedema and neovascular age-related macular degeneration. However, the effect of blocking the VEGF function has not been thoroughly explored in vivo. A previous study has reported that intravitreal injection of bevacizumab had no retinal toxicity on rats; however, bevacizumab is human-specific and does not react with rat VEGF. In this study, the authors examined the effect of anti-rat VEGF antibody and bevacizumab on rat retina in vivo and in vitro, especially focusing on retinal ganglion cells (RGCs). Methods: In vitro, rat RGCs were purified by a two-step immunopanning procedure, and incubated in the presence of VEGF, bevacizumab, anti-rat VEGF antibody, and control-IgG for three days. The number of viable RGCs was counted. In vivo, after intravitreal injections of bevacizumab, anti-rat VEGF antibody, and control-IgG, viable RGCs were visualised by retrolabelling with Fluo-gold and enumerated to examine the toxicity. Results: In vivo, the mean (standard deviation) number of viable RGCs in the VEGF-treated group (0.99 (0.29) vs control), the bevacizumab-treated group (1.0 (0.23) vs control), the anti-rat VEGF antibody-treated group (0.98 (0.18) vs control) and the control IgG-treated group (0.98 (0.19) vs control) was not statistically different from that of the control group after 3 days. In vitro, the mean (SD) number of viable RGCs in the bevacizumab-treated group (2613 (230)/mm2), the anti-rat VEGF antibody-treated group (2600 (140)/mm2) and the control IgG-treated group (2656 (150)/mm2) was not statistically different from that of the control group (2656 (150)/mm2) after 7 days. There were no apparent histological abnormalities. Conclusion: This study suggests that bevacizumab and anti-rat VEGF antibody have no short-term, direct retinal toxicity using the rat model. Intravitreal injection of bevacizumab shows no short-term, direct toxicity on RGCs.
- 2 May 2007
- Published by BMJ in British Journal of Ophthalmology
- Vol. 91 (9) , 1230-1233
Effect of anti-VEGF antibody on retinal ganglion cells in rats
Aim: Intravitreal injection of anti-vascular endothelial growth factor (VEGF) antibody (bevacizumab, Avastin) has become one of the chief choices for the treatment of macular oedema and neovascular age-related macular degeneration. However, the effect of blocking the VEGF function has not been thoroughly explored in vivo. A previous study has reported that intravitreal injection of bevacizumab had no retinal toxicity on rats; however, bevacizumab is human-specific and does not react with rat VEGF. In this study, the authors examined the effect of anti-rat VEGF antibody and bevacizumab on rat retina in vivo and in vitro, especially focusing on retinal ganglion cells (RGCs). Methods: In vitro, rat RGCs were purified by a two-step immunopanning procedure, and incubated in the presence of VEGF, bevacizumab, anti-rat VEGF antibody, and control-IgG for three days. The number of viable RGCs was counted. In vivo, after intravitreal injections of bevacizumab, anti-rat VEGF antibody, and control-IgG, viable RGCs were visualised by retrolabelling with Fluo-gold and enumerated to examine the toxicity. Results: In vivo, the mean (standard deviation) number of viable RGCs in the VEGF-treated group (0.99 (0.29) vs control), the bevacizumab-treated group (1.0 (0.23) vs control), the anti-rat VEGF antibody-treated group (0.98 (0.18) vs control) and the control IgG-treated group (0.98 (0.19) vs control) was not statistically different from that of the control group after 3 days. In vitro, the mean (SD) number of viable RGCs in the bevacizumab-treated group (2613 (230)/mm2), the anti-rat VEGF antibody-treated group (2600 (140)/mm2) and the control IgG-treated group (2656 (150)/mm2) was not statistically different from that of the control group (2656 (150)/mm2) after 7 days. There were no apparent histological abnormalities. Conclusion: This study suggests that bevacizumab and anti-rat VEGF antibody have no short-term, direct retinal toxicity using the rat model. Intravitreal injection of bevacizumab shows no short-term, direct toxicity on RGCs.